^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunomodulator

    Related drugs:
    18h
    L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) (clinicaltrials.gov)
    P=N/A, N=2200, Recruiting, Barcelona Institute for Global Health | Not yet recruiting --> Recruiting | Trial completion date: Apr 2027 --> Aug 2027 | Trial primary completion date: Jan 2027 --> Jun 2027
    Enrollment open • Trial completion date • Trial primary completion date • Adverse events
    22h
    Maimonides Minocycline in Stroke Study (clinicaltrials.gov)
    P2/3, N=2, Terminated, Maimonides Medical Center | N=1120 --> 2 | Recruiting --> Terminated; The protocol is in the process to change due to challenges in recruiting participants (without a treatment arm) which is now reflected in 2024-04-01
    Enrollment change • Trial termination
    |
    minocycline
    1d
    HOPE-3: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov)
    P3, N=106, Active, not recruiting, Capricor Inc. | Trial completion date: Dec 2027 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion date • Trial primary completion date
    1d
    Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (clinicaltrials.gov)
    P1/2, N=24, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Trial completion date: Aug 2027 --> Dec 2029 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    2d
    Low-Dose Naltrexone For ME/CFS: Dose-Finding (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, University of Alabama at Birmingham
    New P2 trial
    2d
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Mar 2028
    Enrollment open • Trial primary completion date
    2d
    AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) (clinicaltrials.gov)
    P1/2, N=190, Not yet recruiting, Arsenal Biosciences, Inc.
    New P1/2 trial
    3d
    Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment (clinicaltrials.gov)
    P1, N=18, Suspended, University of Florida | Trial completion date: Sep 2029 --> Sep 2030 | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    6d
    Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (clinicaltrials.gov)
    P1/2, N=39, Active, not recruiting, BioCardia, Inc. | Enrolling by invitation --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    6d
    ThyroLDN: Does treatment with naltrexone (a medication) improve quality of life in patients with hypothyroidism (underactive thyroid)? (ACTRN12625000131459)
    P2, N=150, Recruiting, St. Vincent's Hospital, Sydney | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • HEOR
    6d
    A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Recruiting, GEn1E Lifesciences | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Separation of Epimers of a Cleavable ADC Drug Linker Using SLIM-Ion Mobility Mass Spectrometry. (PubMed, J Am Soc Mass Spectrom)
    For instance, L-citrulline can be cleaved by cathepsin B, while D-citrulline is not...Using this novel approach, citrulline-containing DL's, compounds A-D, were all baseline resolved with a single set of TWIMS parameters. This work underscores the critical role of high-resolution SLIM-IM-MS in resolving subtle structural differences in chiral ADC components, providing essential insights into their development and quality control.
    Journal
    |
    CTSS (Cathepsin S)